Company: MIRA
Filing Date: 2025-07-29
Form Type: PRER14A
Source: 0001641172-25-021434
Chunk: 207

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-07-29
Form: PRER14A
Chunk 207
---
 Mira grants a sublicense to any third party and receives revenue, Mira agrees to pay Miralogx 8.0% of the revenue received in the aggregate by the Licensee from all such sublicensees. Mira will owe at most 8.0% of all consideration collectively received from all commercial sales and all third parties, excluding commercial sales.

Mira’s Financials

Following are the Company’s audited balance sheets as of December 31, 2023, and December 31, 2024, and the unaudited balance sheet as of April 21, 2025:

| Moore Financial Consulting |

| MIRA Pharmaceuticals, Inc. | April 2025   |
| Valuation                  | Page 7 of 28 |

Following are Mira’s Profit & Loss report for years ended on December 31, 2023 and 2024:

The following are Mira’s Cash Flows reports for the twelve months ended December 31 of the years 2023 and 2024:

| Moore Financial Consulting |

| MIRA Pharmaceuticals, Inc. | April 2025   |
| Valuation                  | Page 8 of 28 |

The Markets

Diabetic Neuropathic Pain (DNP)

Diabetic neuropathic pain (DNP) represents one of the most prevalent and debilitating complications associated with diabetes, accounting for most neuropathic pain cases globally. Epidemiological data indicates that approximately one-third of individuals with diabetes experience DNP 1, underscoring a significant patient population impacted by this condition.

Clinically, DNP is defined by the presence of neuropathic symptoms and/or signs in diabetic patients, following the exclusion of alternative etiologies. The condition arises primarily from prolonged hyperglycemia, which leads to nerve damage, most commonly affecting the lower extremities—specifically the legs and feet.

DNP is typically characterized by a range of sensory disturbances, including burning, tingling, sharp, shooting, or electric shock-like sensations. The intensity of pain is often rated as moderate to severe and tends to worsen during nighttime hours, frequently disrupting sleep.

In addition to persistent pain, many patients experience cutaneous allodynia, where even light touch can provoke significant discomfort. This symptom burden has a substantial negative impact on health-related quality of life, impairing daily functioning, reducing participation in social and recreational activities, and contributing to psychological comorbidities such as depression.

Given its high prevalence, chronic nature, and the profound impact on patient well-being,